Structure Therapeutics (NASDAQ:GPCR) Given Overweight Rating at Cantor Fitzgerald

Structure Therapeutics (NASDAQ:GPCR - Get Free Report)'s stock had its "overweight" rating reissued by research analysts at Cantor Fitzgerald in a research note issued to investors on Friday, Benzinga reports. They presently have a $65.00 target price on the stock. Cantor Fitzgerald's target price suggests a potential upside of 65.44% from the company's current price.

Separately, Lifesci Capital restated an "outperform" rating on shares of Structure Therapeutics in a research report on Tuesday, February 27th. Six analysts have rated the stock with a buy rating, According to MarketBeat, Structure Therapeutics currently has an average rating of "Buy" and a consensus target price of $85.71.

Structure Therapeutics Stock Up 0.8 %

Structure Therapeutics stock traded up $0.30 during trading hours on Friday, hitting $39.29. The stock had a trading volume of 423,228 shares, compared to its average volume of 569,257. The stock has a market cap of $1.83 billion and a price-to-earnings ratio of -47.34. Structure Therapeutics has a one year low of $21.79 and a one year high of $75.02. The business's 50 day simple moving average is $39.37 and its 200-day simple moving average is $47.13.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last issued its quarterly earnings data on Friday, March 8th. The company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.04. Research analysts anticipate that Structure Therapeutics will post -0.98 EPS for the current fiscal year.

Hedge Funds Weigh In On Structure Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. Picton Mahoney Asset Management acquired a new position in shares of Structure Therapeutics during the 3rd quarter valued at $116,000. Sectoral Asset Management Inc. acquired a new stake in shares of Structure Therapeutics in the 4th quarter valued at about $139,000. ADAR1 Capital Management LLC bought a new stake in Structure Therapeutics in the 4th quarter valued at about $163,000. Washington University bought a new position in Structure Therapeutics in the third quarter worth approximately $215,000. Finally, China Universal Asset Management Co. Ltd. grew its stake in Structure Therapeutics by 208.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 4,349 shares of the company's stock valued at $177,000 after acquiring an additional 2,939 shares during the period. 91.78% of the stock is currently owned by institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.